Previous studies have shown no correlation between transition of disease status for Philadelphia chromosome-positive (Ph þ ) chronic myelogenous leukemia (CML) and JAK2 V617F gene mutation. 1, 2 Recently, several novel mutations as well as deletion in exon 12 of the JAK2 gene in JAK2 V617F -negative polycythemia vera 3 and JAK2 K607N mutation in acute myeloid leukemia 4 were reported. Because the JAK-STAT pathway plays an important role in the initiation and progression of Ph þ leukemia, 5, 6 we analyzed these novel mutations and deletion of the JAK2 gene among Ph þ CML patients and Ph þ acute leukemia (Ph þ AL). We examined 88 CML patients, three patients with Ph þ acute lymphocytic leukemia and two patients of Ph þ acute biphenotypic leukemia patients. Bone marrow mononuclear cells were obtained from all patients with a written informed consent.
Among the Ph þ CML cases, 72 patients were in the chronic phase, five patients were in the accelerate phase and 11 were in blast crisis (BC). Five Ph þ CML patients had additional chromosome aberrations and three Ph þ CML patients had double Ph þ chromosomes. As for Ph þ CML treatment, 13 had been treated with interferon-a before administration of imatinib and six patients were imatinib resistant.
We first looked for the JAK2 V617F gene mutation by allelicspecific (AS-) PCR and direct sequencing as described in a previous report. 7 No patients with the JAK2 V617F mutation were identified by AS-PCR. Next, we looked for other mutations in exons 12 and 14 of the JAK2 gene by direct sequencing. 3, 7 Neither mutations nor deletions in exons 12 and 14 of the JAK2 gene were detected in these Japanese Ph þ CML and Ph þ AL patients.
The progression of CML to BC requires telomere shortening, genomic instability, differentiation arrest and loss of tumor suppressor, however, the JAK2 mutations might not be required for these processes. Even so, we think that sequencing of the entire JAK2 gene and analysis of the possible abnormalities in the JAK-STAT pathway may be necessary because BCR/ABL directly regulates STAT5. 8 In conclusion, we could not identify any JAK2 gene mutations or deletions among 88 Ph þ CML and Ph þ AL patients. Although PDGFRB fuses with different partners in myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS), ETV6-PDGFRB is the only fusion gene, which has been recognized to date when a t(5;12)(q33;p13) is present at the karyotypic level. Here, we describe for the first time a new fusion, that is ERC1-PDGFRB in a case of acute myeloid leukemia (AML). To detect reliably t(5;12)(q33;p13)/ERC1-PDGFRB by fluorescence in situ hybridization (FISH) and to differentiate this new fusion from the classical t(5;12)(q33;p13)/ETV6-PDGFRB, we set up a specific double-color double-fusion assay using the RP11-1087E18 clone for the ERC1 gene and the CTD-2601I11 clone for the PDGFRB gene (Figure 1) .
M
A 36-year-old man was referred to the Division of Hematology, Rome, in November 2006 because of a relapsed AML after an autologous stem cell transplantation (auto-SCT). The previous diagnosis of AML M5a had been made in 2002. The past history revealed a slight leukocytosis (14 Â 10 9 /l) from October 2000. On admission, the peripheral blood count was: hemoglobin, 11.4 g/dl, Platelets 97 Â 10 9 /l, white blood cells, 3.1 Â 10 9 /l (polymorphonuclear cells 12%, lymphocytes 63%, monocytes 11%, Blast 14%). Liver and spleen were enlarged. The bone marrow aspirate was hypercellular with a diffuse infiltration of medium and large blasts with basophilic cytoplasm (71% of nucleated cells). Megakaryocytes were dysplastic. The karyotype was 46,XY,t(5;12)(q33;p13.3)[9]/92,XXYY,t(5;12)(q33;p13.3) X2 [12] . Given the 5q33 breakpoint we performed a double-color metaphase FISH with cosmid 9-4 for the 3 0 -PDGFRB (orange) and cosmid 4-1 (green) for the 5 0 -PDGFRB. 1 FISH gave one orange/ green fusion signal on normal five, one orange signal on der(5) and one green signal on der(12), indicating the t(5;12) disrupted PDGFRB. Cosmid 179A6 (5 0 -ETV6) and cosmid 148B6 (3 0 -ETV6) gave two orange/green fusion signals on normal 12 and on der(12), indicating that the 12p13.3 breakpoint mapped telomeric to ETV6.
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FISH with five cosmids for loci/genes localized telomeric to ETV6, that is, cosmid 214C9 for D12S994, cosmid 135H12 for Figure 1 Double-color double-fusion FISH with clone CTD-2601I11 (orange) and clone RP11-1087E18 (green) on bone marrow sample of relapse: arrows indicate der(5) and der(12). Letters to the Editor D12S939, cosmid 139D4 for CACNL1A1, cosmid 152H1 for FGF6 and cosmid 147G1 for NOL1 narrowed the 12p13 breakpoint to a 1 M region, between locus D12S939 and locus D12S994. 2 We hypothesized that ERC1 (ELKS/RAB6-interacting/ CAST family member 1) was a putative partner for PDGFRB since of all the genes mapping within this DNA segment, only ERC1 contains dimerization domains, which are a common feature of all PDGFRB partners. FISH with four DNA clones RP11-359B12, RP4-773N5, RP11-1087E18 and RP11-73H11 encompassing the ERC1 gene from telomere to centromere indicated that the breakpoint fell within clone RP11-1087E18. 3 Nested reverse transcriptase-PCR amplified an ERC1-PDGFRB fusion transcript. Patient RNA was extracted with Trizol (Invitrogen, Carlsbad, CA, USA) from a bone marrow sample and retro-transcribed using the thermoscript RT-PCR system (Invitrogen). The first amplification round was performed with primers ERC1_1756_ex7F (5 0 -GTTGAAGGAGTCCTTGACTG -3 0 ) and PDGFRb_2393R (5 0 -TAGATGGGTCCTCCTTTGGTG -3 0 ) and the second with primers ERC1_2288_ex11F (5 0 -TCTT CTCTGGCATCCTCAGG-3 0 ) and PDGFRBR1 (5 0 -TAAGCATCTT GACGGCCACT-3 0 ). The product was cloned in the pGEM-T Easy Vector System (Promega, Madison, WI, USA). Blast search and sequence analysis showed that nucleotide 3021 (ERC1 exon 15) was involved in an in-frame fusion with nucleotide 1837 (PDGFRb exon 10) (Figure 2a) , and an out-of-frame fusion with nucleotide 2049 (PDGFRb exon 11) (Figure 2b) .
RT-PCR investigated the reciprocal PDGFRB-ERC1 using primers PDGFRb_1121ex5F (5 0 -GTGAACGCAGTGCAGACTG T-3 0 ) and ERC1_ex19_3780R, (5 0 -ATCCAAAGCAGAAAGGCA GA-3 0 ) followed by nested PCR with primers PDGFRb_ 1799ex9F (5 0 -CCGAACATCATCTGGTCTGC-3 0 ) and ERC1_ ex19_3689R (5 0 -AGTGTTTGGTGCCAAGAAGG-3 0 ). We detected and sequenced a PDGFRB-ERC1 in-frame fusion transcript joining nucleotide 1836 (PDGFRb exon 9) to nucleotide 3022 (ERC1 exon 16) (data not shown).
ERC1 maps at 12p13.3, spans 500 kb, is ubiquitously expressed and is characterized by several coiled-coil domains. Interestingly, ERC1, H4(D10S170) and TPM3 are three PDGFRB partners in myeloid malignancies that are also involved in human papillary thyroid carcinoma: ERC1 and H4(D10S170) fuse with RET as a result of t(10;12)(q21;p13) and of inv(10) (q11.2q21), producing the ERC1-RET and the H4(D10S170)-RET autophosphorylated tyrosine kinase, respectively; 4,5 TPM3 rearranges with the nearby neurotrophic tyrosine kinase receptor type 1 (NTRK1/1q23) gene. 6 The efficacy of imatinib mesylate on PDGFRB-positive chronic myeloproliferative disorders was first reported by Apperley et al. 7 in four patients, including one patient with aggressive disease with severe and diffuse skin localization who failed to respond to corticosteroid, hydroxyurea and interferon a. Since PDGFRB was involved in our patient, imatinib mesylate (400 mg/day) was administered for 2 weeks followed by chemotherapy. 8 After induction chemotherapy imatinib was restarted. At 30 days from the end of chemotherapy the patient was in hematological and FISH remission (as assessed with genomic clones for PDGFRB). RT-PCR showed persistence of the ERC1-PDGFRB transcript, which progressively decreased under imatinib treatment but did not disappear. In April 2007, the patient underwent a family unrelated SCT which has been followed at day þ 20, date of the first marrow monitoring by a disappearance of the ERC1-PDGFRB transcript.
In conclusion we have identified a new partner of PDGFRB, that is the ERC1 gene which has so far never been involved in hematological malignancies. Based on the results of this report we wish to highlight that the ERC1-PDGFRB cannot be differentiated from the ETV6-PDGFRB rearrangement by conventional cytogenetics and that, as expected, this new PDGFRB recombination is sensitive to treatment with imatinib.
